Sullivan Helps Amgen In $1.2B Micromet Buy
California-based Amgen said it would pay $11 per share for Maryland-based Micromet, a price unanimously approved by both companies' boards of directors.
"The acquisition of Micromet is an opportunity to acquire an innovative oncology asset with global rights and a validated technology platform with broad potential clinical applications," Amgen CEO Kevin Sharer said.
Amgen said one of...
To view the full article, register now.